ReviewOphthalmic plastic and reconstructive surgery
Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
Review in Ophthalmic plastic and reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 94 citations in OpenAlex.
- Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.JAMA ophthalmology · 2020Trial
- Insights into basal cell carcinoma with bone metastasis: a comprehensive review.Skin health and disease · 2025Review
- A Systematic Review and Meta-Analysis of Ocular and Periocular Basal Cell Carcinoma with First-Time Description of Dermoscopic and Reflectance Confocal Microscopy Features of Caruncle Basal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- [New systemic treatment approaches for malignant eyelid tumors].Die Ophthalmologie · 2025Review
- Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration.Eye (London, England) · 2023Article
- Review
- [Therapeutic alternatives to surgical treatment of malignant eyelid tumors and their precursors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Periocular basal cell carcinoma - clinical perspectives.Oncology reviews · 2020Article
- Epithelial conjunctival neoplasias - the importance of an early diagnosis and optimal treatment.GMS ophthalmology cases · 2020Article
- Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.Chinese medical journal · 2019Article
- TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR.Oncogenesis · 2018Article
- Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.Open access Macedonian journal of medical sciences · 2018Review
- Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.Current oncology reports · 2017Review
- Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.Eye (London, England) · 2017Article
- Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.OncoTargets and therapy · 2017Review
- [Therapy options for malignant eyelid tumors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.Journal of cancer research and clinical oncology · 2016Article
- Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.World journal of clinical cases · 2014Review
- Oral smoothened inhibitor for advanced basal cell carcinoma of the hand: a case report.Hand (New York, N.Y.) · 2014Article
- Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.Ophthalmic plastic and reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo review the literature on targeted therapy for orbital and periocular basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) and provide examples of patients recently treated with such therapy.
methodsThe authors reviewed the literature on clinical results of targeted therapy and the molecular basis for targeted therapy in orbital and periocular BCC and cutaneous SCC. The authors also present representative cases from their practice.
resultsMutation in the patched 1 gene (PTCH1) has been implicated in BCC, and overexpression of epidermal growth factor receptor (EGFR) has been shown in SCC. Vismodegib, an inhibitor of smoothened, which is activated upon binding of hedgehog to Ptc, has been shown to significantly decrease BCC tumor size or even produce complete resolution, especially in cases of basal cell nevus syndrome. Similarly, EGFR inhibitors have been shown to significantly decrease SCC tumor size in cases of locally advanced and metastatic disease. The authors describe successful outcomes after vismodegib treatment in a patient with basal cell nevus syndrome with numerous bulky lesions of the eyelid and periocular region and erlotinib (EGFR inhibitor) treatment in a patient with SCC who was deemed not to be a good surgical candidate because of advanced SCC of the orbit with metastasis to the regional lymph nodes, advanced age, and multiple medical comorbidities.
conclusionsTargeted therapy using hedgehog pathway and EGFR inhibitors shows significant promise in treatment of orbital and periocular BCC and cutaneous SCC, respectively. Such targeted therapy may be appropriate for patients who are not good candidates for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.